Mumps Vaccine in Japan- low coverage of mumps-containing vaccinat | 41282
Pediatrics & Therapeutics

Pediatrics & Therapeutics
Open Access

ISSN: 2161-0665

+44 1478 350008

Mumps Vaccine in Japan- low coverage of mumps-containing vaccination and studies toward its inclusion into national immunization program in Japan

Joint Event on 16th Annual World Congress on Pediatrics & 3rd Annual World Congress on Pediatric Nutrition, Gastroenterology & Child Development

March 21-22, 2018 | New York, USA

Taito Kitano

Nara Prefecture General Medical Center, Japan

Scientific Tracks Abstracts: Pediatr Ther

Abstract :

The coverage rate of mumps vacccine is 30-40% for one-dose in Japan. The reasons of low coverage is that the govenment does not include mumps vaccine into National Immunization Program (NIP). Major governmental concerns for inclusion are social will, cost-effectiveness, aseptic meningitis as one of adverse events. Aseptic meningitis after vaccination made the goverment stop routine mumps vaccinaation since 1993; however, it has been shown that incoodence of aseptic meningitis was as 1/5,000-7,000 (Hoshino and Torii strains) at 1 year old which was lower than expected. In this presentation, the studies about cost-effectiveness analyses and social will will be indroduced. First, static model simulation was performed and resulted that cost-benefit ratios were 3.69 and 6.84 in independent inoculation and simultaneous inoculation, respectively, from a social perspective. In addition, dynamic transmission model was used to consider herd immunity with the result that two-dose vacination program was always dominating over one-dose or current program in all scenarios. In terms of social will, a questionnaire survey was performed to Japanese parents if they wish that mumps vaccines are included into NIP after giving current information. The result was that 95.0% of parents want routine mumps vacccination In countries with high coverages of two-dose vaccines, mumps outbreaks still exist. Once Japanese goverment approve routine vaccination, we can compare the effiicacies between Jeryl-Lynn strain and Japanese strain and further investigate the best vaccine strain and schedule.

Biography :

Taito Kitano has completed his MD at the age of 24 years from Nara Medical University and is in part-time MPH studies from Johns Hopkins Bloomberg School of Public Health. He is a pediatrician at Nara Prefecture General Medical Center. He has published a paper about cost-effectiveness analysis of mumps vaccination in Japan.